Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kristi Ott

Nurse Practitioner Kansas City, MO Nurse Practitioner

NPI 1184743650 CMS profile 10612312

4321 Washington Street, Suite 5600, Kansas City, MO 64111

Open in the dashboard

General payments

$6,415

290 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristi Ott of Kansas City, MO is reported in the CMS Open Payments database as having received $6,415 across 290 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,387 106
2024 General $2,269 104
2023 General $1,650 79
2021 General $109 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristi Ott
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Kristi Ott were reported at $2,387. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Kristi Ott Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $109 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $1,650 $166 $54–$529 $160
2024 $2,269 $173 $55–$556 $164
2025 $2,387 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,782 95 payments
  2. Janssen Biotech, Inc. $1,002 33 payments
  3. Lilly USA, LLC $552 23 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $522 26 payments
  5. Ardelyx, Inc. $348 14 payments
  6. Aimmune Therapeutics, Inc. $232 11 payments
  7. Celgene Corporation $208 13 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $207 8 payments
  9. Organon LLC $166 7 payments
  10. Celltrion USA Inc. $159 9 payments
  11. Other $1,237 51 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,143 283 payments
  2. Education $273 7 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $1,095 59 payments
  2. OMVOH $552 23 payments
  3. STELARA $530 16 payments
  4. SKYRIZI Immunology $518 25 payments
  5. SKYRIZI Immunology $505 30 payments
  6. ENTYVIO $490 24 payments
  7. TREMFYA $472 17 payments
  8. LINZESS $437 24 payments
  9. CREON $423 24 payments
  10. IBSRELA $348 14 payments
  11. Other $2,462 111 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

587

Median for Nurse Practitioner: 389

Drug cost

$80,431

Median for Nurse Practitioner: $21,885

Branded share of claims

16%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 19 $47,559
Linzess Linaclotide Brand 24 $15,103
Nexium Esomeprazole Magnesium Brand 13 $10,580
Colestipol Hcl Generic 52 $2,098
Pantoprazole Sodium Generic 224 $1,513
Ondansetron Odt Ondansetron Brand 38 $1,047
Omeprazole Generic 120 $954
Sucralfate Generic 16 $501
Esomeprazole Magnesium Generic 14 $424
Dicyclomine Hcl Generic 32 $381

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OMVOH
  • Lilly USA, LLC $317
$317 — —
STELARA
  • Janssen Biotech, Inc. $309
$309 — —
SKYRIZI
  • AbbVie, Inc. $227
$227 — —
RINVOQ
  • AbbVie, Inc. $187
$187 — —
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $132
$132 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

290 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record